Otolith Labs has developed a novel wearable medical device that is on track to be the first FDA approved device for the treatment of vertigo through the De Novo process in 2023. The technology provides immediate relief of symptoms in approximately 80% of vertigo cases based on pilot clinical data. Founded by Sam Owen in 2015, Otolith Labs is backed by investors that include Radical Investments LP and is headquartered in Washington.